Medicinova (MNOV)Insider sold ~$1.73M

~$1.73M

Approx. value · 640K sh @ $2.70

4.86M

Holds after · shares reported

Traded

Sep 25, 2026

Filed

Sep 29, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 17, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 17, 2026, MediciNova, Inc. (the “Company”) entered into new Executive Employment Agreements (collectively, the “Agreements”) with each of Yuichi Iwaki, M.D., Ph.D., the Company’s President and Chief Executive Officer, and Kazuko Matsuda, M.D., Ph.D., MPH, the Company’s Chief Medical Officer (each of Dr. Iwaki and Dr. Matsuda, the “Executive”).”
2. Aug 31, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
3. Sep 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
4. Sep 25, 2026 · this disclosureInsiderInsider sold ~$1.73M of MNOV shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Medicinova

For Medicinova, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MNOV page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans